Fig 1.
Study schema for MTN-030/IPM 041.
Fig 2.
Study schema for MTN-044/IPM 053/CCN019.
Fig 3.
Framework for evaluating acceptability in microbicide and PrEP trials [37].
Table 1.
Baseline characteristics by study and study arm (MTN-030/IPM 041 [n = 23] and MTN-044/IPM 053/CCN019 [n = 25]).
Table 2.
Acceptability by study (MTN-030/IPM 041 [n = 23] and MTN-044/IPM 053/CCN019 [n = 25]) and by study arm.
Fig 4.
Heatmap of bleeding patterns, MTN-030/IPM 041 (n = 23).
green = no bleeding, yellow = light bleeding, pink = moderate bleeding, red = heavy bleeding.
Table 3.
Adherence (expulsions and removals) and bleeding incidence by study (MTN-030/IPM 041 [n = 23] and MTN-044/IPM 053/CCN019 [n = 25]) and by study arm.
Fig 5.
Heatmap of bleeding patterns, MTN-044/IPM 053/CCN019 (n = 25).
green = no bleeding, yellow = light bleeding, pink = moderate bleeding, red = heavy bleeding.
Table 4.
Impact of product characteristics, adherence, and bleeding patterns on overall acceptability, by study (MTN-030/IPM 041 [n = 23] and MTN-044/IPM 053/CCN019 [n = 25]).